ReviewNatural products and bioprospecting2025
Marine natural products as a source of novel anticancer drugs: an updated review (2019-2023).
Review in Natural products and bioprospecting, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Article
- Selenium-Containing 1,4-Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple-Negative Breast Cancer Cells.Drug development research · 2026Article
- From Marine Peptides to Oncology: The Therapeutic Potential of Conotoxins in Cancer Treatment.Chemistry & biodiversity · 2026Review
- Article
- Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition.Marine drugs · 2026Article
- Immunotherapeutic and Antitumoral Potential of Fatty Acids from Subantarctic Macroalgae (Sarcopeltis skottsbergii).Marine biotechnology (New York, N.Y.) · 2026Article
- Discovery of New Zosteropenillines from the Seagrass-Derived FungusMarine drugs · 2026Article
- Algae-Derived Bioactive Compounds as Platforms for Translational Biotechnology and Health Applications.Biotech (Basel (Switzerland)) · 2026Review
- Marine-Derived Neoagarotetraose Alleviates Dry Eye Disease by Suppressing Inflammation and Apoptosis in a Murine Model.Marine drugs · 2026Article
- Erythroside: A New Cerebroside and Other Compounds From Erythrina Caffra Thunb. (Fabaceae) Stem Bark, With Cytotoxicity and Antioxidant Evaluation.Chemistry & biodiversity · 2026Article
- Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation.Marine drugs · 2026Article
- Fungi as a source of anticancer agents: metabolic products and their functional implications.Archives of microbiology · 2026Review
- Computational screening of natural phenolic compounds as potential EGFR inhibitors against triple negative breast cancer.Journal of molecular modeling · 2025Article
- Antiproliferative effect of Filopaludina bengalensis fluid inducing apoptosis-necroptosis synergy with immunogenic remodelling in triple-negative breast cancer.Scientific reports · 2025Article
- Screening Based on Structural and Biological Verification of Stachyose as a PPARγ-Modulating Ligand for the Treatment of Non-Alcoholic Fatty Liver Disease.Food science & nutrition · 2025Article
- Secondary Metabolites of the Marine Sponge-Derived FungusMarine drugs · 2025Article
- Artificial intelligence-assisted optimization of Eichhornia crassipes extracts and evaluation of their biological activities.Scientific reports · 2025Article
- 3‑Phenethyl-2-phenylquinazolin-4(3ACS pharmacology & translational science · 2025Article
- The Cytotoxic Activity of Secondary Metabolites from Marine-DerivedMarine drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine natural products have long been recognized as a vast and diverse source of bioactive compounds with potential therapeutic applications, particularly in oncology. This review provides an updated overview of the significant advances made in the discovery and development of marine-derived anticancer drugs between 2019 and 2023. With a focus on recent research findings, the review explores the rich biodiversity of marine organisms, including sponges, corals, algae, and microorganisms, which have yielded numerous compounds exhibiting promising anticancer properties. Emphasizing the multifaceted mechanisms of action, the review discusses the molecular targets and pathways targeted by these compounds, such as cell cycle regulation, apoptosis induction, angiogenesis inhibition, and modulation of signaling pathways. Additionally, the review highlights the innovative strategies employed in the isolation, structural elucidation, and chemical modification of marine natural products to enhance their potency, selectivity, and pharmacological properties. Furthermore, it addresses the challenges and opportunities associated with the development of marine-derived anticancer drugs, including issues related to supply, sustainability, synthesis, and clinical translation. Finally, the review underscores the immense potential of marine natural products as a valuable reservoir of novel anticancer agents and advocates for continued exploration and exploitation of the marine environment to address the unmet medical needs in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.